Advertisement
Screener

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

1.5 / 5 stars · 18/60 Roast Me

TONIX PHARMACEUTICALS HOLDING CORP. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $7.17 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-11.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-11

  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $2.48M, a 9.36% decline year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $4.69M, a 0.51% decline year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $3.90M.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $5.24M.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $16.59M.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$24.17M.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$392.00K.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$15.00K.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 79 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 82 month
2017-06-30$2.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
$7.17M
10-Q · filed 2017-08-11
$11.07M
derived: sum of 3 quarters · filed 2017-08-11
$16.31M
derived: sum of 4 quarters · filed 2017-08-11
2017-03-31$4.69M
10-Q · filed 2017-05-12
$8.60M
derived: sum of 2 quarters · filed 2017-05-12
$13.84M
derived: sum of 3 quarters · filed 2017-05-12
$16.57M
derived: sum of 4 quarters · filed 2017-08-11
2016-12-31$3.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-13
$9.14M
derived: sum of 2 quarters · filed 2017-04-13
$11.88M
derived: sum of 3 quarters · filed 2017-08-11
$16.59M
10-K · filed 2017-04-13
2016-09-30$5.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
$7.97M
derived: sum of 2 quarters · filed 2017-08-11
$12.69M
10-Q · filed 2016-11-10
$10.77M
derived: sum of 4 quarters · filed 2017-08-11
2016-06-30$2.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
$7.45M
10-Q · filed 2017-08-11
$5.53M
derived: sum of 3 quarters · filed 2017-08-11
-$16.57M
derived: sum of 4 quarters · filed 2017-08-11
2016-03-31$4.72M
10-Q · filed 2017-05-12
$2.79M
derived: sum of 2 quarters · filed 2017-05-12
-$19.30M
derived: sum of 3 quarters · filed 2017-05-12
-$19.45M
derived: sum of 4 quarters · filed 2017-05-12
2015-12-31-$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-13
-$24.02M
derived: sum of 2 quarters · filed 2017-04-13
-$24.17M
derived: sum of 3 quarters · filed 2017-04-13
-$24.17M
10-K · filed 2017-04-13
2015-09-30-$22.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
-$22.25M
derived: sum of 2 quarters · filed 2016-11-10
-$22.25M
10-Q · filed 2016-11-10
-$22.37M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30-$153.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
-$153.00K
10-Q · filed 2016-08-05
-$278.00K
derived: sum of 3 quarters · filed 2016-08-05
-$438.00K
derived: sum of 4 quarters · filed 2016-08-05
2015-03-31$0.00
10-Q · filed 2016-05-06
-$125.00K
derived: sum of 2 quarters · filed 2016-05-06
-$285.00K
derived: sum of 3 quarters · filed 2016-05-06
-$390.00K
derived: sum of 4 quarters · filed 2016-05-06
2014-12-31-$125.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
-$285.00K
derived: sum of 2 quarters · filed 2016-03-03
-$390.00K
derived: sum of 3 quarters · filed 2016-03-03
-$392.00K
10-K · filed 2016-03-03
2014-09-30-$160.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06
-$265.00K
derived: sum of 2 quarters · filed 2015-11-06
-$267.00K
10-Q · filed 2015-11-06
-$274.00K
derived: sum of 4 quarters · filed 2016-03-03
2014-06-30-$105.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07
-$107.00K
10-Q · filed 2015-08-07
-$114.00K
derived: sum of 3 quarters · filed 2016-03-03
-$122.00K
derived: sum of 4 quarters · filed 2016-03-03
2014-03-31-$2.00K
10-Q · filed 2015-05-08
-$9.00K
derived: sum of 2 quarters · filed 2016-03-03
-$17.00K
derived: sum of 3 quarters · filed 2016-03-03
-$17.00K
derived: sum of 4 quarters · filed 2016-03-03
-$156.00K
10-Q · filed 2014-05-13
2013-12-31-$7.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03
-$15.00K
derived: sum of 2 quarters · filed 2016-03-03
-$15.00K
derived: sum of 3 quarters · filed 2016-03-03
-$15.00K
10-K · filed 2016-03-03
-$154.00K
10-K · filed 2014-03-28
2013-09-30-$8.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07
-$8.00K
derived: sum of 2 quarters · filed 2014-11-07
-$8.00K
10-Q · filed 2014-11-07
2013-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08
$0.00
10-Q · filed 2014-08-08
2013-03-31$0.00
10-Q · filed 2014-05-13
2012-12-31-$36.00K
10-K · filed 2014-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Annexon, Inc. (ANNX)United States$0.147B-4.22
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91